A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE
Would Be Second US Drug For Eosinophilic Esophagitis
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.
You may also be interested in...
Despite a priority review being granted late last year by the FDA, Takeda has announced the surprise withdrawal of the US BLA for its dengue vaccine TAK-003, for reasons it said centered on "data collection" issues. The quadrivalent vaccine has already been approved as Qdenga in several other markets including the EU, Indonesia and Thailand and the future path in the US is currently uncertain.
New Phase III results set stage for a potential US submission in high-need indication of congenital thrombotic thrombocytopenic purpura in the next few months if company sticks to initial development plans.
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.